Evidence map›Paper›PMID 35638575›Full record

ArticleJournal of cell science2022

MKLP2 functions in early mitosis to ensure proper chromosome congression.

Morgan S Schrock, Luke Scarberry, Benjamin R Stromberg, Claire Sears, Adrian E Torres, David Tallman, Lucas Krupinski, Arnab Chakravarti, Matthew K Summers

Open access · bronzeAbstract read
In one paragraph

Article in Journal of cell science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Morgan S SchrockDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Luke ScarberryDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Benjamin R StrombergDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Claire SearsDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Adrian E TorresDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
David TallmanDepartment of Internal Medicine, The Ohio State University, Columbus, OH 43210, USA.
Lucas KrupinskiDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Arnab ChakravartiDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.
Matthew K SummersDepartment of Radiation Oncology, Arthur G. James Comprehensive Cancer Center and Richard L. Solove Research Institute, The Ohio State University, Columbus, OH 43210, USA.ORCID 0000-0002-2482-0332
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · USKenyon College · USThe Ohio State University · US

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Renato Martins · 1985 to 2026
$51.0M
The OSU Center for Clinical and Translational Science: Advancing Today's Discoveries to Improve HealthUL1TR002733 · NCATS · OHIO STATE UNIVERSITY · PI RINGEL, MATTHEW D · 2018 to 2022
$28.9M
Genetic evolution of glioblastomas during radiation and temozolomide therapyR01CA188228 · NCI · DANA-FARBER CANCER INST · PI BEROUKHIM, RAMEEN, CHAKRAVARTI, ARNAB · 2015 to 2025
$6.9M
Determining the role of lipid droplets in glioblastoma and their therapeutic potentialR01NS104332 · NINDS · OHIO STATE UNIVERSITY · PI Deliang Guo · 2018 to 2026
$4.2M
Ohio State University Neuroscience Center Core-Core EP30NS104177 · NINDS · OHIO STATE UNIVERSITY · PI BROWN, ANTHONY · 2017 to 2020
$1.9M
Defining the molecular mechanisms regulating the hexosamine-N-glycosylation pathway in glioblastomaR01CA227874 · NCI · OHIO STATE UNIVERSITY · PI CHAKRAVARTI, ARNAB, GUO, DELIANG · 2019 to 2023
$1.5M
Mechanisms of Spindle Assembly Checkpoint SilencingR01GM108743 · NIGMS · OHIO STATE UNIVERSITY · PI SUMMERS, MATTHEW K · 2014 to 2017
$1.2M
Dissecting functional interplay of deubiquitinases and the cell cycle machineryR01GM112895 · NIGMS · OHIO STATE UNIVERSITY · PI SUMMERS, MATTHEW K · 2015 to 2018
$1.2M
American Brain Tumor AssociationNCATS NIH HHS UL1 TR002733NCI NIH HHS P30 CA016058NCI NIH HHS P30 CA016059NCI NIH HHS R01 CA188228NCI NIH HHS R01 CA227874NIGMS NIH HHS R01 GM108743NIGMS NIH HHS R01 GM112895NINDS NIH HHS P30 NS104177NINDS NIH HHS R01 NS104332Ohio State University
6 · The paper itself

Abstract

Mitotic kinesin-like protein 2 (MKLP2; also known as KIF20A) is a motor protein with a well-established function in promoting cytokinesis. However, our results with siRNAs targeting MKLP2 and small-molecule inhibitors of MKLP2 (MKLP2i) suggest that it also has a function earlier in mitosis, prior to anaphase. In this study, we provide direct evidence that MKLP2 facilitates chromosome congression in prometaphase. We employed live imaging to observe HeLa cells with fluorescently tagged histones treated with MKLP2i and discovered a pronounced chromosome congression defect. We show that MKLP2 facilitates error correction, as inhibited cells have a significant increase in unstable, syntelic kinetochore-microtubule attachments. We find that the aberrant attachments are accompanied by elevated Aurora kinase (A and B) activity and phosphorylation of the downstream target HEC1 (also known as NDC80) at Ser55. Finally, we show that MKLP2 inhibition results in aneuploidy, confirming that MKLP2 safeguards cells against chromosomal instability. This article has an associated First Person interview with the first author of the paper.

Indexed as

MitosisAurora Kinase BChromosomesChromosome SegregationHeLa CellsHumansKinesinsKinetochoresMicrotubulesSpindle ApparatusAurora Kinase BKIF20A protein, humanKinesinsAurora kinaseChromosome congressionKIF20AMKLP2Motor kinesin

Identifiers

PMID35638575
PMCPMC9270953
OpenAlexW4281892178

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.